In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Glover, Jason M, Loriaux, Marc, Tyner, Jeffrey W, Druker, Brian J, Chang, Bill H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2012
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291800/
https://www.ncbi.nlm.nih.gov/pubmed/22038978
http://dx.doi.org/10.1002/pbc.23383
_version_ 1782225177603473408
author Glover, Jason M
Loriaux, Marc
Tyner, Jeffrey W
Druker, Brian J
Chang, Bill H
author_facet Glover, Jason M
Loriaux, Marc
Tyner, Jeffrey W
Druker, Brian J
Chang, Bill H
author_sort Glover, Jason M
collection PubMed
description Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.
format Online
Article
Text
id pubmed-3291800
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Wiley Subscription Services, Inc., A Wiley Company
record_format MEDLINE/PubMed
spelling pubmed-32918002013-02-25 In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia Glover, Jason M Loriaux, Marc Tyner, Jeffrey W Druker, Brian J Chang, Bill H Pediatr Blood Cancer Brief Reports Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL. Wiley Subscription Services, Inc., A Wiley Company 2012-09 /pmc/articles/PMC3291800/ /pubmed/22038978 http://dx.doi.org/10.1002/pbc.23383 Text en Copyright © 2011 Wiley Periodicals, Inc. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Brief Reports
Glover, Jason M
Loriaux, Marc
Tyner, Jeffrey W
Druker, Brian J
Chang, Bill H
In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title_full In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title_fullStr In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title_full_unstemmed In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title_short In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia
title_sort in vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-b acute lymphoblastic leukemia
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291800/
https://www.ncbi.nlm.nih.gov/pubmed/22038978
http://dx.doi.org/10.1002/pbc.23383
work_keys_str_mv AT gloverjasonm invitrosensitivitytodasatinibinlymphoblastsfromapatientwitht1719q22p13generearrangementprebacutelymphoblasticleukemia
AT loriauxmarc invitrosensitivitytodasatinibinlymphoblastsfromapatientwitht1719q22p13generearrangementprebacutelymphoblasticleukemia
AT tynerjeffreyw invitrosensitivitytodasatinibinlymphoblastsfromapatientwitht1719q22p13generearrangementprebacutelymphoblasticleukemia
AT drukerbrianj invitrosensitivitytodasatinibinlymphoblastsfromapatientwitht1719q22p13generearrangementprebacutelymphoblasticleukemia
AT changbillh invitrosensitivitytodasatinibinlymphoblastsfromapatientwitht1719q22p13generearrangementprebacutelymphoblasticleukemia

Ejemplares similares